Furthermore, we found that this anti-HER2 targeted treatment-associated positive effect was even more powerful in patients whose tumours also had strong expression of Akt2 as well as cytoplasmic and nuclear localization of pAkt (pAkt Thr308 and/or pAkt Ser473). The gene discussed is AKT2; the disease is neoplasm.